

DYNAVAX TECHNOLOGIES CORP

Form 8-K

July 03, 2007

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, DC 20549**

**FORM 8-K  
CURRENT REPORT  
PURSUANT TO SECTION 13 OR 15(D) OF THE  
SECURITIES AND EXCHANGE ACT OF 1934**  
Date of report (Date of earliest event reported): **June 28, 2007**  
**DYNAVAX TECHNOLOGIES  
CORPORATION**  
(Exact name of registrant as specified in charter)

**Delaware**  
(State or other  
jurisdiction of  
incorporation)

**000-50577**  
(Commission File Number)

**33-0728374**  
(I.R.S. Employer  
Identification No.)

**2929 Seventh Street, Suite 100  
Berkeley, California 94710**

(Address of principal executive offices and zip code)  
Registrant's telephone number, including area code: **(510) 848-5100**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 8.01. Other Events.**

In a press release dated June 28, 2007, Dynavax Technologies Corporation ( Dynavax ) announced that it has entered into a license agreement with Coley Pharmaceutical Group, Inc. ( Coley ) relating to certain of Coley s TLR Therapeutics patents. Under the terms of the agreement, Dynavax receives a non-exclusive license under Coley s immunostimulatory oligonucleotide patent estate for the commercialization of HEPLISAV , a hepatitis B prophylactic vaccine, currently in Phase 3 clinical trials. Dynavax will make a \$5.0 million up-front payment to Coley. Coley is also eligible to receive up to an additional \$5.0 million upon regulatory approvals of HEPLISAV , as well as royalty payments for any future sales of HEPLISAV .

The press release dated June 28, 2007, titled Coley Pharmaceutical Group Grants Dynavax License for Commercialization of HEPLISAV is attached hereto as Exhibit 99.1 and is herein incorporated by reference.

**Item 9.01. Financial Statements and Exhibits.**

(d) Exhibits.

<b>Exhibit No.</b>	<b>Description</b>
99.1	Press release, dated June 28, 2007, entitled Coley Pharmaceutical Group Grants Dynavax License for Commercialization of HEPLISAV .

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

**Dynavax Technologies Corporation**

Dated: July 2, 2007

By: /s/ Michael Ostrach  
Michael Ostrach, Vice President, Chief  
Business Officer and General Counsel

3

---

**INDEX TO EXHIBITS**

<b>Exhibit Number</b>	<b>Description</b>
99.1	Press release, dated June 28, 2007, entitled Coley Pharmaceutical Group Grants Dynavax License for Commercialization of HEPLISAV .

4